CBPO [China Biologic Products] SC 13D: (Original Filing)
[]
RENN [Renren] SC 13G/A: (Original Filing)
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
RENN [Renren] SC 13G/A: SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Commences Phase III Clinical Trials for COVID-19
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
NCTY [The9] F-1/A:
[] [THE9 LIMITED CLASS A ORDINARY SHARES, PAR VALUE US$0.01 PER SHARE IN THE FORM OF AMERICAN DEPOSITARY SHARES UNDERWRITING AGREEMENT [●], 2020 Maxim Group LLC As Representative of the several Underwriters named in Schedule I attached hereto Ladies and Gentlemen: Company Underwriters Agreement” Repr]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
SVA [SINOVAC BIOTECH] 6-K: Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
SGOC [SGOCO] 6-K: (Original Filing)
[SGOCO Group, Ltd. Appoints New Director The Company today announced that the Board of Directors of the Company has appointed Mr. Mark Leonard Tan (“Mr. Tan”) as the director of the Company, effective on September 23, 2020 to replace Mr. Hok Fung Wai who notified his resignation from the Board, effec]
